Clinical Trials Browser

Phase 2 × Carcinoma × Gefitinib × Clear all

NCT00519077 2016-07-01

Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck

Phase 2 Completed

44 enrolled 7 charts

Carcinoma, Head and Neck Neoplasms, Neoplasms